The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study.
Emre YekedüzDeniz Turalİsmail ErtürkSerdar KarakayaCihan ErolÖzlem ErcelepÇağatay ArslanÖzlem Nuray SeverSaadettin KılıçkapNihan Şentürk ÖztaşAhmet KüçükardaOrçun CanBerna ÖksüzoğluMehmet Ali ŞendurNuri KaradurmuşYuksel UrunPublished in: Journal of cancer research and clinical oncology (2022)
This study established that pre-treatment PIV might be a prognostic biomarker in patients with mRCC treated with nivolumab in the second line and beyond.